Other
Human Germline Genome Editing – Genetics bodies weigh in on debate with position paper
11 August 2017 - Posted by: Daniel Lim
In an article published in American Journal of Human Genetics on 3 August 2017, an international group of 11 organisations with genetics expertise has issued a joint position statement, setting out 3 key positions on the question of human germline genome editing: At this time, given the nature and number of unanswered scientific, ethical, and › Read More
BeneluxA collaboration joint pricing negotiations fail
25 July 2017 - Posted by: Eveline Van Keymeulen
The first joint pricing negotiations for a medicinal product in the context of the BeneluxA collaboration with respect to health technology assessment and pricing and reimbursement have failed. On 23 May 2017, the Belgian Minister of Health announced that the Belgian National Institute for Health and Disability Insurance (RIZIV), joined by the Dutch competent authorities, › Read More
20 July 2017 - Posted by: Patricia Carmona Botana
Last week, the Health Ministers of Portugal and Spain signed a letter of intent that marks the beginning of a joint procurement, funding and price negotiation initiative for medicines and medical devices in the Iberian region. The initiative seeks to enhance cooperation in order to improve patients’ safety, patient’s access to innovative treatments, as well › Read More
A CRISPR patent pool – one step closer to reality?
19 July 2017 - Posted by: Robyn Trigg
In a press release on 10 July 2017, the Broad Institute announced that is has, with joint patent owners Harvard University, the Massachusetts Institute of Technology and the Rockefeller University, entered discussions about a potential CRISPR patent pool. The institutions collectively submitted 22 patents (from 10 patent families) for consideration to be included in a › Read More
Australian Government’s compensation claim against pharma patentees rumbles on…
18 May 2017 - Posted by: Jin Ooi
Commonwealth of Australia v Sanofi [2017] FCA 382 is the latest development in the Australian Government’s bid to recover substantial compensation against Sanofi pursuant to cross-undertakings in damages given by Sanofi in interim injunction proceedings against Apotex. Why is the wider case of interest? The case began in 2007 when, in exchange for obtaining interlocutory › Read More